Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2021
• Auteurs : Tim HarrisonPascal ChanezFrancesco MenzellaGiorgio Walter CanonicaRenaud LouisBorja CosioNjira LugogoArjun MohanAnnie BurdenLawrence McdermottEsther Garcia GilJames ZangrilliWolfgang PohlRobert VovesMaud DeschampheleireJean-Benoit MartinotRudi PechéKenneth ChapmanAmarjit CheemaDelbert DorscheidJ. Mark FitzgeraldRemi GagnonWilliam Patrick KillornRonald OlivensteinGeorge PhilteosClare RamseyJ. Douglass RolfBrandie WalkerOle HilbergTina SkjoldIngrid TitlestadAuli HakulinenMaritta KilpeläinenMichèle Ben HayounPhilippe BonniaudArnaud BourdinFrédéric de BlayGaëtan DesleeGilles DevouassouxAlain DidierYoucef DouadiStéphanie FryGilles GarciaPierre-Olivier GirodetChristophe LeroyerAntoine MagnanGuillaume MahayCécilia NocentChristophe PisonPauline-Marie RouxCamille TailléJuliana-Angelica TiotiuEkkehard BeckMargret JandlChristian KaehlerFrank KässnerFrank KoestersJuliane KronsbeinThomas SchaumChristian SchulzDirk SkowaschChristian TaubeTobias WelteAndrés de RouxBianca BeghéFrancesco BlasiGiovanna CarpagnanoCristiano CarusoAngelo Guido CorsicoElio ConstantinoNunzio CrimiPiero MaestrelliManlio MilaneseAlberto PapiGirolamo PelaiaLaura PiniPierachille SantusEleonora SaviNicola ScichiloneGianenrico SennaGiuseppe SpadaroAdriano VaghiSteven GansJurgen HöltersB. LangeveldWillem PietersG.H.A. StaaksIlonka van VeenJ.W.K. van den BergGunnar EinvikSverre LehmannIsmael Ali GarcíaCarlos AlmonacidIrina BoboleaPaloma Campo MozoGustavo de LuizChristian Domingo RibasJosé María Echave-Sustaeta María-ToméJuan Luis García RiveroBorja García-Cosío PiquerasAna Gómez-Bastero FernándezRuperto González PérezAythamy Henríquez SantaCarlos Martínez RiveraXavier Muñoz GallJacinto RamosJose Gregorio Soto CamposCarmen Vidal PanNikolai StenforsAlf TunsäterInes VingeRekha ChaudhuriTimothy HarrisonAdel MansurShuaib NasserMonica NordstromPaul PfefferDinesh SaralayaPhilip ShortArun AdlakhaOral AlpanFrancis AverillAnil BadhwarJose BardelasBarbara BaxterGeorge BenschWilliam BergerJonathan BernsteinTracy BridgesRyan BrimeyerWilliam CalhounEdward CampbellWilliam Brett CherryGeoffrey ChuppLee CloreJohn CohnJeremy ColeJohn CondemiJames CuryBenjamin DavisSamuel DeleonLuis DelacruzJoseph DiazDavid ErbEmeka EziriFaisal FakihDouglas FiedlerDavid FostStephen FritzErika GonzalezBrad GoodmanPeter GottliebGregory GottschlichRichard GowerRizan HajalJames HarrisHengameh Heidarian-RaissyAlbrecht HeyderDavid HillFernando HolguinIftikhar HussainJonathan IllowiteJoshua JacobsMikell JarrattHarold KaiserNeil KaoRavindra KashyapDavid KaufmanEdward KentKenneth KimRyan KleinMonica KraftRitsu KonoShahrukh KureishyJeffrey LefleinMila LeongHuamin LiRobert LinMichael MarcusDiego Jose Maselli CaceresVinay MehtaCurtis MelloMark MillardAaron MilstoneWendy MooreMark MossNayla MumnehThomas O'BrienDavid OstranskyMichael PalumboPurvi ParikhSudhir ParikhAmit PatelGuido PerezWarren PleskowBruce PrennerDileep PuppalaJohn RameyJoan ReibmanRamon ReyesEmory RobinetteIleana RodicioStephen RyanSudhir SekhsariaBarry SigalVinay SikandWeily SoongSelwyn SpangenthalRoy St. JohnGary StevenVijay SubramaniamKaharu SuminoEric SztejmanRicardo TanTonny TanusCharles ThompsonCarl ThornbladeManuel VillarealSally WenzelHeidi ZafraTomasz Ziedalski
• Organismes :
• Publié dans The Lancet Respiratory Medicine le 23/10/2020

---

Résumé : Background: ANDHI was done to assess the efficacy of benralizumab, including onset of effect and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and nasal polyposis symptoms. Methods: This phase 3b, randomised, double-blind, parallel-group, placebo-controlled ANDHI study was completed in adults (aged 18–75 years) with severe eosinophilic asthma with at least 2 exacerbations in the previous year, despite high-dose inhaled corticosteroid plus additional controllers, screening blood eosinophil counts of at least 150 cells per μL, and an Asthma Control Questionnaire 6 (ACQ-6) score of 1·5 or more. Patients who met eligibility criteria were randomly assigned (2:1; stratified by previous exacerbation count [two, or three or more], maintenance oral corticosteroid use, and region), using an integrated web-based response system, to receive benralizumab at 30 mg every 8 weeks (first three doses given 4 weeks apart) or matched placebo for 24 weeks. Primary efficacy measure was annualised asthma exacerbation rate, with rate ratio (RR) calculated over the approximate 24-week follow-up. Secondary efficacy measures included change from baseline to end of treatment (week 24) in St George's Respiratory Questionnaire (SGRQ) total score (key secondary endpoint), FEV1, peak expiratory flow (PEF), ACQ-6, Predominant Symptom and Impairment Assessment (PSIA), Clinician Global Impression of Change (CGI-C), Patient Global Impression of Change (PGI-C), and Sino-Nasal Outcome Test-22 (SNOT-22). All efficacy analyses, except for SNOT-22, were summarised and analysed using the full analysis set on an intention-to-treat population (all randomly assigned patients receiving investigational product, regardless of protocol adherence or continued participation in the study). SNOT-22 was summarised for the subgroup of patients with physician-diagnosed nasal polyposis with informed consent. This study is registered with ClinicalTrials.gov, NCT03170271. Findings: Between July 7, 2017, and Sept 25, 2019, 656 patients received benralizumab (n=427) or placebo (n=229). Baseline characteristics were consistent with severe eosinophilic asthma. Benralizumab significantly reduced exacerbation risk by 49% compared with placebo (RR estimate 0·51, 95% CI 0·39–0·65; p<0·0001) over the 24-week treatment period and provided clinically meaningful and statistically significant improvement from baseline to week 24 in SGRQ total score versus placebo (least squares mean change from baseline −8·11 (95% CI −11·41 to −4·82; p<0·0001), with similar differences at earlier timepoints. Benralizumab improved FEV1, PEF, ACQ-6, CGI-C, PGI-C, PSIA, and SNOT-22 at week 24 versus placebo, with differences observed early (within weeks 1 to 4). Adverse events were reported for 271 (63%) of 427 patients on benralizumab versus 143 (62%) of 229 patients on placebo. The most commonly reported adverse events for the 427 patients receiving benralizumab (frequency >5%) were nasopharyngitis (30 [7%]), headache (37 [9%]), sinusitis (28 [7%]), bronchitis (22 [5%]), and pyrexia (26 [6%]). Fewer serious adverse events were reported for benralizumab (23 [5%]) versus placebo (25 [11%]), and the only common serious adverse event (experienced by >1% of patients) was worsening of asthma, which was reported for nine (2%) patients in the benralizumab group and nine (4%) patients in the placebo group. Interpretation: Our results extend the efficacy profile of benralizumab for patients with severe eosinophilic asthma, showing early clinical benefits in patient-reported outcomes, HRQOL, lung function, and nasal polyposis symptoms

---

Fichiers liés : 2021 Harrison et al., Onset of effect and impact.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2021
• Auteurs : Merwan MokhtariPhilippe Pagnod-RossiauxChristophe LevalloisFrancois LaruelleDaniel T CassidyMauro BettiatiJean-Pierre Landesman
• Organismes : Institut de Physique de Rennes 3SP Technologies Institut des Fonctions Optiques pour les Technologies de l'informatiON 3SP Technologies McMaster University [Hamilton, Ontario] 3SP Technologies Institut des Fonctions Optiques pour les Technologies de l'informatiON
• Publié dans Applied Physics Letters le 01/11/2020

---

Résumé : We report an investigation of the strain field in mesa structures for oxide-confined vertical-cavity surface-emitting lasers (VCSELs) using the polarization-resolved micro-photoluminescence (PL) measurement of the degree of polarization (DOP) at room temperature. The DOP of the PL is correlated with the spatial distribution of the embedded anisotropic strain in a VCSEL structure. Measurements normal to (100) surfaces of the samples and from (110) cross-sectional planes were performed. The effect of two processes required in the fabrication of GaAs-based VCSELs was studied: the plasma etching of the P-doped distributed Bragg reflector and the wet oxidation process used to control current flow and lateral optical confinement. The DOP method allows very sensitive measurements of the mechanical strain (on the order of 10 - 5) accumulated in VCSEL devices even during different steps of the fabrication process.

---

Fichiers liés : Mechanical strain mapping of GaAs based VCSELs.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2021
• Auteurs : Tania PetersenThibault MahévasPauline CannetJean-David BouazizCamille HuaCharles ZarnitskyPhilippe ModianoFrançois LifermannBruno SassolasOlivier CarpentierArsène MékinianLaurent GarderetPierre AucouturierYannick Chantran
• Organismes : CHU Saint-Antoine [AP-HP] Centre de Recherche Saint-Antoine CHU Saint-Antoine [AP-HP] CHU Saint-Antoine [AP-HP] Centre de Recherche Saint-Antoine Service de Dermatologie [AP-HP Hôpital Saint-Louis] Service de dermatologie [Mondor] Epidemiology in Dermatology and Evaluation in Therapeutics Groupe Hospitalier du Havre Hôpital Jacques Monod (MONTIVILLIERS) Hôpital Saint Vincent de Paul [Lille] Centre Hospitalier de Dax Hôpital de la Cavale Blanche - CHRU Brest Hôpital Provo CHU Saint-Antoine [AP-HP] CHU Pitié-Salpêtrière [AP-HP] CHU Saint-Antoine [AP-HP] Centre de Recherche Saint-Antoine CHU Saint-Antoine [AP-HP] Centre de Recherche Saint-Antoine
• Publié dans Clinical Laboratory le 31/10/2020

---

Résumé : Background: Scleromyxedema (SME) is a rare mucinosis associated with monoclonal gammopathy. Several biochemical peculiarities of monoclonal immunoglobulins (Ig) in SME patients were reported in case reports or short series, such as IgGλ over-representation, cationic migration, and partial deletion. Methods: Monoclonal immunoglobulins (Ig) from the serum of 12 consecutive patients diagnosed with scleromyxedema (SME) were analyzed using electrophoretic and immunoblotting techniques. Results: All monoclonal Ig from 12 SME were of IgG1 subclass, with an overrepresentation of the lambda-type light chain and a cationic mobility on standard zone electrophoresis, as compared with 21 cases of monoclonal gammopathy of undetermined significance (MGUS) of IgG1 subclass. Reactivity with specific monoclonal antibodies demonstrated no evident deletion of the heavy chain constant domains, which was also confirmed by analysis of Ig heavy chain molecular weight on a purified monoclonal component from one case. Conclusions: Significant isotype restriction of both heavy and light chains, and peculiar biochemical properties suggest that monoclonal Ig might be involved in pathophysiological events of SME.

---

Fichiers liés : #200605 Petersen et al 2020 manuscript revised1_DHO pa final.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2021
• Auteurs : Claire DupuisClément Le BihanDaniele MaubonLaure CalvetStéphane RucklyCarole SchwebelLila BouadmaElie AzoulayMuriel CornetJean-Francois TimsitRebecca Hamidfar-RoyMagalie CiroldiClichy Catherine Paugam-BurtzArnaud FoucrierJean Christophe NavellouMichel WolffJean-Francois TimsitLila BouadmaBruno MourvillierRomain SonnevilleSarah ChemamDidier GrusonBertrand SouweineAlexandre LautrettePierre Emmanuel CharlesRémi BruyereMaël HametBernard AllaouchicheChristian GuillaumeCharles-Eric BerJohanne ProthetThomas RimmeleLaurent ArgaudMarie SimonMartin CourRomain HernuSamir JaberBoris JungMathieu ConseilYannael CoiselFouad BelafiaKada KloucheLaurent AmiguesSonia MachadoMarianne ServeauxJean ChastreJean-Louis TrouilletJoël CoussonPascal RaclotThierry FlochFabrice ZeniMichael DarmonMatthias PichonMaud CoudrotSebastien NinetEric DiconneBenoit SchlemmerElie AzoulayVirginie LemialeNicolas MaziersFerhat MezianiDavid SchnellJulie Boisrame-HelmsRaluca Neagu-AncaXavier DelabrancheOlivier MartinetMaité Garrouste-OrgeasBenoit MissetFabrice BruneeVirginie LaurentGuillaume LacaveJean-Pierre BedosKhadija HammiLenka StyfalovaJoelle FritzschSophie LetrouLucie EstevezTherese DevauxCeline DubienSoumia BayarassouCatherine Jouvene FaureSylvie de La SalleAlbert PradesAnnie RodriguezPierre MeurMagda WarcholHanane El HaouariIgor TheodoseJulien FournierSebastien CavelotLilia Bakir KodjaMarie Joyeux-FaureFrédéric TaccoSonia RoosKarima DupreMalek AbazidMichele EssertPhilippe ArnaudEmmanuelle PapyBellabes GhezzoulOlivier GerbouinSandrine Corny PeccouxPhilippe FagnoniAnne MillaretChristine PivotCecile GerardCyril BreukerAudrey CastetFanny CharbonnierMaryline LegrandJulia MordiniIsabelle Madeleine ChambrinAnne Hutt ClaussMohamed CherifiAnne PattynMuriel CornetDanièle MaubonEliane BenvenisteFrédéric GrenouilletChristian ChochillonIsabelle AccoberryDenis PonsNatacha MrozekFrédéric DalleStephane PicotFrancoise BeyerleAnne-Lise BienvenuNathalie BourgeoisArnaud FekkarDominique ToubasHélène RaberinErmanno CandolfiValérie BruMarie Dominique KitzisYaye SenghorCatherine PaletteStéphane RucklyAurélien VesinJean-Paul MiraJean-Ralph ZaharDominique LarreyJean-Pierre ZarskiJean-Ralph ZaharJean-Paul MiraDominique LarreyJean-Pierre ZarskiEdith Schir
• Organismes : CHU Gabriel Montpied [Clermont-Ferrand] Unité de Nutrition Humaine Infection, Anti-microbiens, Modélisation, Evolution Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Universitaire [CHU Grenoble] Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525 Translational microbial Evolution and Engineering CHU Clermont-Ferrand Université de Paris, IAME, INSERM, Paris, France Hôpital Michallon Université Grenoble Alpes Infection, Anti-microbiens, Modélisation, Evolution AP-HP - Hôpital Bichat - Claude Bernard [Paris] Hopital Saint-Louis [AP-HP] Translational microbial Evolution and Engineering Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525 Centre Hospitalier Universitaire [CHU Grenoble] Université de Paris, IAME, INSERM, Paris, France Unité de soins intensifs médicaux et infectieux [AP-HP Hôpital Bichat-Claude-Bernard] Clinique de réanimation médicale Hôpital Beaujon [AP-HP] Service de Réanimation médicale [CHRU Besançon] Université Paris Diderot - Paris 7 AP-HP - Hôpital Bichat - Claude Bernard [Paris] Université de Paris, IAME, INSERM, Paris, France Unité de soins intensifs médicaux et infectieux [AP-HP Hôpital Bichat-Claude-Bernard] Infection, Anti-microbiens, Modélisation, Evolution AP-HP - Hôpital Bichat - Claude Bernard [Paris] Hôpital universitaire Robert Debré [Reims] Université de Reims Champagne-Ardenne AP-HP - Hôpital Bichat - Claude Bernard [Paris] CHU Trousseau [APHP] Centre Hospitalier Universitaire [CHU Grenoble] Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525 Translational microbial Evolution and Engineering Centre Hospitalier Universitaire [CHU Grenoble] Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525 Translational microbial Evolution and Engineering
• Publié dans Open Forum Infectious Diseases le 22/10/2020

---

Résumé : Abstract Background We aimed to assess the prognostic value of repeated measurements of serum (1–3)-β-D-glucan (BDG), mannan-antigen (mannan-Ag), and antimannan antibodies (antimannan-Ab) for the occurrence of invasive candidiasis (IC) in a high-risk nonimmunocompromised population. Methods This was a preplanned ancillary analysis of the EMPIRICUS Randomized Clinical Trial, including nonimmunocompromised critically ill patients with intensive care unit–acquired sepsis, multiple Candida colonization, and multiple organ failure who were exposed to broad-spectrum antibacterial agents. BDG (>80 and >250 pg/mL), mannan-Ag (>125 pg/mL), and antimannan-Ab (>10 AU) were collected repeatedly. We used cause-specific hazard models. Biomarkers were assessed at baseline in the whole cohort (cohort 1). Baseline covariates and/or repeated measurements and/or increased biomarkers were then studied in the subgroup of patients who were still alive at day 3 and free of IC (cohort 2). Results Two hundred thirty-four patients were included, and 215 were still alive and free of IC at day 3. IC developed in 27 patients (11.5%), and day 28 mortality was 29.1%. Finally, BDG >80 pg/mL at inclusion was associated with an increased risk of IC (CSHR[IC], 4.67; 95% CI, 1.61–13.5) but not death (CSHR[death], 1.20; 95% CI, 0.71–2.02). Conclusions Among high-risk patients, a first measurement of BDG >80 pg/mL was strongly associated with the occurrence of IC. Neither a cutoff of 250 pg/mL nor repeated measurements of fungal biomarkers seemed to be useful to predict the occurrence of IC. The cumulative risk of IC in the placebo group if BDG >80 pg/mL was 25.39%, which calls into question the efficacy of empirical therapy in this subgroup.

---

Fichiers liés : 2021 Dupuis et al., Open Forum Infect Dis.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2021
• Auteurs : Marco PappaccogliSilvia Di MonacoEwa Warchoł-CelińskaAurélien LorthioirLaurence AmarLucas AparicioChristophe BeauloyeRosa Maria BrunoPatrick ChenuPeter de LeeuwTine de BackerPhilippe DelmotteZivka DikaDaniel GordinHilde HeutenYoshio IwashimaJean-Marie KrzesinskiAbraham KroonLucia MazzolaiEsteban PochPantelis A. SarafidisChristophe SeinturierWilko SpieringL ToubianaPatricia van Der NiepenDaan van TwistAdriana VisonàJean-Claude WautrechtHelena WitowiczJianzhong XuAleksander PrejbiszAndrzej JanuszewiczAnne BlanchardAlexandre PersuFrank HammerPierre GoffetteParla AstarciAndré PeetersRobert VerhelstMiikka VikkulaFrank van TussenbroekSofie GevaertDimitri HemelsoetLuc DefreyneLaetitia YperzeeleThijs van Der ZijdenJean-Philippe LengeléMuriel SpryngerPeter VerhammeThomas VanasschePasquale ScoppettuoloWouter VinckVassilev DobrinYaneva TeodoraJiguang WangBojan JelakovićIlkka TikkanenMaarit VenermoR MäkeläPierre-François PlouinXavier JeunemaitreAntoine ChédidElie MousseauxOlivier OrmezzanoChristopher SeinturierFrédéric ThonyFelix MahfoudSaarraaken KulenthiranAlexia PiperidouMichael DoumasGeorge StergiouDemetrios VlahakosCaitriona CanningYehonatan SharabiAlberto MorgantiStefano TaddeiCaterina RomaniniIlaria PetrucciFranco RabbiaGian Paolo RossiSilvia LercoPietro MinuzGiancarlo MansuetoSergio de MarchiDenise MarconPatrizia SalicePaola BigolinViviana ZingarettiRosario CianciMarialuisa ZeddeMaria Chiara MatteucciOsami KawaradaYoshito KadoyaBram KroonBert-Jan van den BornAud HøieggenMartin Skage SommerAdam WitkowskiJacek KądzielaAleksandra SoplińskaKrzysztof PieluszczakKatarzyna Jóżwik-PlebanekMagdalena JanuszewiczElżbieta FlorczakPiotr DobrowolskiEva SzabóováMarek HudákMatej MoščovičJuan Diego MediavillaFernando Jaen AguilaAnna OliverasJulian SeguraJose PradoNicolas Roberto RoblesEnrique Montagud-MarrahiAlicia MolinaElena GuillenMarta BurrelPatricia Fernàndez de La LlamaAntonio Barros-MembrillaAnders GottsäterGregor WuerznerGiacomo BusoFaiçal JarrayaHanen ChakerDavid AdlamConstantina ChrysochouNeeraj DhaunRobert HunterIain MacintyreDavid Webb
• Organismes : CIC - HEGP
• Publié dans Cardiovascular Research le 29/10/2020

---

Résumé : Abstract Aims Since December 2015, the European/International Fibromuscular Dysplasia (FMD) Registry enrolled 1022 patients from 22 countries. We present their characteristics according to disease subtype, age and gender, as well as predictors of widespread disease, aneurysms and dissections. Methods and results All patients diagnosed with FMD (string-of-beads or focal stenosis in at least one vascular bed) based on computed tomography angiography, magnetic resonance angiography, and/or catheter-based angiography were eligible. Patients were predominantly women (82%) and Caucasians (88%). Age at diagnosis was 46 ± 16 years (12% ≥65 years old), 86% were hypertensive, 72% had multifocal, and 57% multivessel FMD. Compared to patients with multifocal FMD, patients with focal FMD were younger, more often men, had less often multivessel FMD but more revascularizations. Compared to women with FMD, men were younger, had more often focal FMD and arterial dissections. Compared to younger patients with FMD, patients ≥65 years old had more often multifocal FMD, lower estimated glomerular filtration rate and more atherosclerotic lesions. Independent predictors of multivessel FMD were age at FMD diagnosis, stroke, multifocal subtype, presence of aneurysm or dissection, and family history of FMD. Predictors of aneurysms were multivessel and multifocal FMD. Predictors of dissections were age at FMD diagnosis, male gender, stroke, and multivessel FMD. Conclusions The European/International FMD Registry allowed large-scale characterization of distinct profiles of patients with FMD and, more importantly, identification of a unique set of independent predictors of widespread disease, aneurysms and dissections, paving the way for targeted screening, management, and follow-up of FMD.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2021
• Auteurs : Laure LacanNacim BetrouniM. D. LamblinL. ChatonArnaud DelvalJ. L. BourriezLaurent StormePhilippe DerambureSylvie Nguyen The Tich
• Organismes : Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 Evaluation des technologies de santé et des pratiques médicales - ULR 2694 Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837
• Publié dans Neurophysiologie Clinique = Clinical Neurophysiology le 01/11/2020

---

Résumé : AbstractObjectivesTo identify relevant quantitative parameters for early classification of neonatal hypoxic-ischemic encephalopathy (HIE) severity from conventional EEGs.MethodsNinety EEGs, recorded in full-term infants within 6 h of life after perinatal hypoxia, were visually classified according to the French EEG classification into three groups of increasing HIE severity.Physiologically significant EEG features (signal amplitude, continuity and frequency content) were automatically quantified using different parameters. The EEG parameters selection was based on their ability to reproduce the visual EEG classification. Post hoc analysis based on clinical outcome was performed.ResultsSix EEG parameters were selected, with overall EEG classification performances between 61% and 70%. All parameters differed significantly between group 3 (severe) and groups 1 (normal-mildly abnormal) and 2 (moderate) EEGs (p < 0.001). Amplitude and discontinuity parameters were different between the 3 groups (p < 0.01) and were also the best predictors of clinical outcome. Conversely, pH and lactate did not differ between groups.DiscussionThis study provides quantitative EEG parameters that are complementary to visual analysis as early markers of neonatal HIE severity. These parameters could be combined in a multiparametric algorithm to improve their classification performance. The absence of relationship between pH lactate and HIE severity reinforces the central role of early neonatal EEG.

---

Fichiers liés : S0987705320301477.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2021
• Auteurs : Aurélien DinhJacques RopersClara DuranBenjamin DavidoLaurène DeconinckMorgan MattOlivia SenardAurore LagrangeSabrina MakhloufiGuillaume MellonVictoire de LastoursFrédérique BouchandEmmanuel MathieuJean-Emmanuel KahnElisabeth RouveixJulie GrenetJennifer DumoulinThierry ChinetMarion PépinVéronique DelceySylvain DiamantisDaniel BenhamouVirginie VitratMarie-Christine DombretBertrand RenaudChristian PerronneYann-Eric ClaessensJosé LabarèreJean-Pierre BedosPhilippe AegerterAnne-Claude Crémieux
• Organismes : Assistance publique - Hôpitaux de Paris (AP-HP) Assistance publique - Hôpitaux de Paris (AP-HP) Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525 Centre Hospitalier Universitaire [CHU Grenoble]
• Publié dans The Lancet le 02/11/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2021
• Auteurs : Antoine YrondiGuillaume VaivaMichel WalterThierry A. d'AmatoFrank BellivierDjamila BennabiThierry BougerolVincent CamusOlivier DoumyJean-Baptiste GentyEmmanuel HaffenJérôme HoltzmannMathilde HornChristophe LançonMarion LeboyerPierre-Michel LlorcaJulia MaruaniRémi MoirandFanny MolièreJean PetrucciRaphaelle RichieriLudovic SamalinL. SchmittFlorian StephanPhilippe CourtetWissam El-HageBruno AouizerateV. BarteauS. BensalemH. LaouamriKarmene SouryisL. MalletL. YonD. PierreM. SarrailI. RyffE. BeuchetG. TioC. CappeE. ClercM. GarnierR.M. HonciucE. AllauzeO. BlancN. AllailiI. NietoJ. MeheustY. SunthavyM. PolosanP. CourvoisierB. FredembachS. Foubert-AndreaniFrédéric HaesebaertC. DubienM. LefebvreA. MeznadJérôme BrunelinP. PeriM. FaugereC. Faget-AgiusJ.P. BoulengerC. Mesmeur
• Organismes : Fondation FondaMental [Créteil] Centre Hospitalier Universitaire de Toulouse Toulouse NeuroImaging Center Fondation FondaMental [Créteil] Centre Hospitalier Régional Universitaire [CHU Lille] Fondation FondaMental [Créteil] Hopital de Bohars - CHRU Brest Soins Primaires, Santé Publique, Registre des cancers de Bretagne Occidentale Fondation FondaMental [Créteil] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Centre Hospitalier le Vinatier [Bron] Fondation FondaMental [Créteil] Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris] Optimisation thérapeutique en Neuropsychopharmacologie Fondation FondaMental [Créteil] Centre d'Investigation Clinique de Besançon Laboratoire de Neurosciences Intégratives et Cliniques - UFC (UR 481) Fondation FondaMental [Créteil] [GIN] Grenoble Institut des Neurosciences Centre Hospitalier Universitaire [CHU Grenoble] Fondation FondaMental [Créteil] Imaging, Brain & Neuropsychiatry Centre d’Investigation Clinique [Tours] CIC 1415 Fondation FondaMental [Créteil] Centre hospitalier Charles Perrens [Bordeaux] Nutrition et Neurobiologie intégrée Fondation FondaMental [Créteil] CHU Henri Mondor [Créteil] Fondation FondaMental [Créteil] Centre d'Investigation Clinique de Besançon Laboratoire de Neurosciences Intégratives et Cliniques - UFC (UR 481) Fondation FondaMental [Créteil] [GIN] Grenoble Institut des Neurosciences Centre Hospitalier Universitaire [CHU Grenoble] Fondation FondaMental [Créteil] Centre Hospitalier Régional Universitaire [CHU Lille] Fondation FondaMental [Créteil] Hôpital de la Conception [CHU - APHM] Fondation FondaMental [Créteil] CHU Henri Mondor [Créteil] Fondation FondaMental [Créteil] CHU Clermont-Ferrand Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux Fondation FondaMental [Créteil] Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris] Optimisation thérapeutique en Neuropsychopharmacologie Fondation FondaMental [Créteil] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Centre Hospitalier le Vinatier [Bron] Fondation FondaMental [Créteil] Centre Hospitalier Régional Universitaire [Montpellier] Neuropsychiatrie : recherche épidémiologique et clinique Fondation FondaMental [Créteil] CHU Henri Mondor [Créteil] Fondation FondaMental [Créteil] Hôpital de la Conception [CHU - APHM] Fondation FondaMental [Créteil] CHU Clermont-Ferrand Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux Fondation FondaMental [Créteil] Centre Hospitalier Universitaire de Toulouse Toulouse NeuroImaging Center Fondation FondaMental [Créteil] Hopital de Bohars - CHRU Brest Soins Primaires, Santé Publique, Registre des cancers de Bretagne Occidentale Fondation FondaMental [Créteil] Centre Hospitalier Régional Universitaire [Montpellier] Neuropsychiatrie : recherche épidémiologique et clinique Fondation FondaMental [Créteil] Imaging, Brain & Neuropsychiatry Centre d’Investigation Clinique [Tours] CIC 1415 Fondation FondaMental [Créteil] Centre hospitalier Charles Perrens [Bordeaux] Nutrition et Neurobiologie intégrée
• Publié dans Journal of Psychiatric Research le 26/10/2020

---

Résumé : Objective: In addition to heredity, exposure to early-life adversity is an important predisposing risk factor of suicidal behaviour. Although the association between Childhood Trauma (CT) and suicide risk is well documented, interactions between CT and suicidal behaviour in Treatment-Resistant Depression (TRD) populations have received little coverage. This study aimed to evaluate i) association between CT and suicidal behaviour in a TRD population, and ii) the role of personality traits and impulsiveness as potential factors of mediation in these associations. Methods: Patients were recruited from a cohort of the French network of TRD expert centers. Depressive symptom severity, CT, suicidal behaviour, personality traits, and impulsiveness were assessed with the Montgomery-Åsberg Depression Rating Scale (MADRS), the Childhood Trauma Questionnaire (CTQ), the Columbia Suicide Severity Rating Scale (CSSRS), the Structured Clinical Interview for DSM-IV, the Big Five Inventory, and the Barratt Impulsivness Scale (BIS) respectively. Results: Among the 256 patients with a baseline CTQ, in relation to suicide risk for the current depressive episode, we found an association with the total CTQ scores mediated by the intensity of the current episode in a model adjusted for age and sex (total effect: β = 0.171; p = 0.011, direct effect: β = 0.135; p = 0.043; indirect effect: β = 0.036; p = 0.048). Focusing on CT subtypes, we detected an association between suicide risk and physical neglect in a model adjusted for age and sex (β = 0.301; p = 0.002), without any mediation by the intensity of the current episode. There was no mediation effect from personality traits nor impulsiveness. With regards to CSSRS to assess suicidal ideation, we did not find any association with the total CTQ score and CT subtype scores. Conclusion: We report a strong association between suicidal behaviour and CT (in particular childhood physical neglect) in a TRD population.

---

Fichiers liés : S0022395620311638.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2021
• Auteurs : Pascal PujolMassimo BarberisPhilp BeerEitan FriedmanJosep M PiulatsEttore D CapoluongoJesus Garcia FoncillasIsabelle Ray-CoquardFrédérique Penault-LlorcaWilliam FoulkesClare TurnbullHelen HansonSteven NarodBanu K ArunMatti S AaproJean-Louis MandelNicola NormannoDiether LambrechtsIgnace VergoteMichèle AnahoryBernard BaertschiKaren BaudryYves-Jean BignonMarc BolletCarole CorsiniOlivier CussenotThibault de La Motte RougeMarie Duboys de LabarreFlorence DuchampClarisse DuriezKarim FizaziVirginie GalibertLaurence GladieffJoseph GligorovPascal HammelMarion Imbert-BouteilleWilliam JacotTatiana Kogut-KubiakPierre-Jean LamyDaphné LehalleYann NeuzilletSylviane OlschwangXavier RébillardJean-Marc ReyChloé RideauJean-Philippe SpanoFrédéric ThomasIsabelle TreilleuxMarion VandrommeJulie VendrellMichèle VintraudDaniel ZarcaKevin S HughesMichèle VintraudJose E Alés Martínez
• Organismes : Centre de Recherches Ecologiques et Evolutives sur le Cancer European Institute of Oncology [Milan] The Wellcome Trust Sanger Institute [Cambridge] Chaim Sheba Medical Center Tel Aviv University CEINGE Biotecnologie Avanzate s.c.a.r.l. Health Service and Performance Research Imagerie Moléculaire et Stratégies Théranostiques Centre Jean Perrin [Clermont-Ferrand] Department of Human Genetics [Montréal] McGill University = Université McGill [Montréal, Canada] The Institute of Cancer Research Queen Mary University of London The Royal Marsden NHS Foundation Trust [London] The Institute of Cancer Research University of Toronto The University of Texas M.D. Anderson Cancer Center [Houston] Institut de Génétique et de Biologie Moléculaire et Cellulaire VIB-KU Leuven Center for Cancer Biology Universitair Ziekenhuis Leuven = University Hospital of Leuven = Hopital universitaire de Louvain Comité d'éthique de l'Inserm = The Inserm Ethics Committee Université de Genève = University of Geneva Centre Hospitalier Régional Universitaire [Montpellier] Centre Jean Perrin [Clermont-Ferrand] Imagerie Moléculaire et Stratégies Théranostiques Institut Rafaël Centre Hospitalier Régional Universitaire [Montpellier] Groupe de Recherche Clinique Onco-Urologie Prédictive Centre de Recherche pour les Pathologies Prostatiques [Paris] University of Oxford Chemistry, Oncogenesis, Stress and Signaling CRLCC Eugène Marquis Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Régional Universitaire [Montpellier] Institut Gustave Roussy Oncologie génito-urinaire [Gustave Roussy] Centre Hospitalier Régional Universitaire [Montpellier] Oncopole Claudius Regaud Pôle IUCT [CHU Toulouse] CHU Tenon [AP-HP] Institut Universitaire de Cancérologie [Sorbonne Université] Hôpital Beaujon [AP-HP] Centre Hospitalier Régional Universitaire [Montpellier] Institut régional de Cancérologie de Montpellier Centre Hospitalier Régional Universitaire [Montpellier] Clinique Beau Soleil [Montpellier] Lipides - Nutrition - Cancer [Dijon - U1231] Centre de génétique - Centre de référence des maladies rares, anomalies du développement et syndromes malformatifs (CHU de Dijon) UFR Sciences de la santé Simone Veil Marseille medical genetics - Centre de génétique médicale de Marseille Clinique Beau Soleil [Montpellier] Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Régional Universitaire [Montpellier] Epidémiologie, Systèmes d'Information, Modélisation CHU Pitié-Salpêtrière [AP-HP] Centre de Recherches Ecologiques et Evolutives sur le Cancer Centre Léon Bérard [Lyon] Institut de Recherche en Cancérologie de Montpellier Harvard Medical School [Boston]
• Publié dans European Journal of Cancer le 22/10/2020

---

Résumé : BRCA1 and BRCA2 gene pathogenic variants account for most hereditary breast cancer and are increasingly used to determine eligibility for PARP inhibitor (PARPi) therapy of BRCA-related cancer. Because issues of BRCA testing in clinical practice now overlap with both preventive and therapeutic management, updated and comprehensive practice guidelines for BRCA genotyping are needed. The integrative recommendations for BRCA testing presented here aim to (1) identify individuals who may benefit from genetic counselling and risk-reducing strategies; (2) update germline and tumour-testing indications for PARPi-approved therapies; (3) provide testing recommendations for personalised management of early and metastatic breast cancer; and (4) address the issues of rapid process and tumour analysis. An international group of experts, including geneticists, medical and surgical oncologists, pathologists, ethicists and patient representatives, was commissioned by the French Society of Predictive and Personalised Medicine (SFMPP). The group followed a methodology based on specific formal guidelines development, including (1) evaluating the likelihood of BRCAm from a combined systematic review of the literature, risk assessment models and expert quotations, and (2) therapeutic values of BRCAm status for PARPi therapy in BRCA-related cancer and for management of early and advanced breast cancer. These international guidelines may help clinicians comprehensively update and standardise BRCA testing practices.

---

Fichiers liés : Pujol-2021-Clinical practice guidelines for BRCA1 and BRCA2.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/03/2021
• Auteurs : Thomas SanniéPhilippe de MoerlooseBrigitte AlbertLudovic AnaniClaire ArcéTatiana Priscilla BagloCheikh BahaydeMohamed Abdallahi BollahiJean‐michel BouchezSabine CastetIrene ChamiBernard DavietAbdou Ramane DialloMaimouna DialloMaryse DienSaliou DiopAlexis Elira DokekiasGaetan DuportJean‐françois DuportGini EhunguAloys FashahoMohamhed Wenne FeilNorbert FerréChristian FondanescheNicolas GiraudYves GruelJean‐christophe GrisErwan GuillouAssad HaffarEleonore KafandoAimable KanyamunhungaGuelor KatendiDorothée KindeGueth KundabiMichel Du Laurent de La BarreAlain Marques Marques‐verdierSalomé MekhuzlaMaguy MichaudSylvestre MulindabyumaJames NdahayoYacouba NébiéJean‐paul NgoukoulouFabrice PilorgéClaire PouplardNicolas de PoursacOlivat Alson RakotoAnne RymanOlivia Romero‐luxFrançois SauvêtreGhislaine SawadogoJean‐françois SchvedEmmanuel SerombaBouna SowDiariatou Sy‐bahBrigitte Tardy-PoncetCatherine TernisienPierre ToulonMarc TrossaertDavid VirenqueAlain WeillEkhtel Benina ZeinAlban ZohounAristide ZongoAugustin Zoungrana
• Organismes : Université de Genève = University of Geneva
• Publié dans Haemophilia le 25/10/2020

---

Résumé : Introduction: There is a lack of joint recommendations by healthcare professionals (HCP) and patient organizations when a partnership between high and low-income countries in the field of haemophilia is planned. Aim: To draft recommendations to clarify the methodology when a partnership between low- and high-income countries is planned with the objective of a long-term implication. This methodology is to be implemented for fulfilling both medical and associative aims. Methods: Based on the available literature, a first document was written, then diffused to AFATH (Alliance Franco-Africaine pour le Traitement de l'Hémophilie) members, and after a one-day meeting and further amendments, a second draft was approved by all members before submission for publication. Results: Based on 6 years experience, several recommendations regarding the joint and separate roles of patient association and HCP for a first mission in French-speaking sub-Saharan African countries have been established. The proposed methodology for establishing preliminary contacts, the first visit and the key points for diagnostic action, medical follow-up, patient education and advocacy strategy outlines a model of partnership between patients and HCP. Conclusion: This paper written jointly by patients and physicians underlines the importance of reciprocal expert guidance and a partnership based on complementary inputs.

---

Source